Protection of pigs against 'in contact' challenge with classical swine fever following oral or subcutaneous vaccination with a recombinant porcine adenovirus.
A recombinant porcine adenovirus expressing the classical swine fever virus (CSFV) gp55 gene (rPAdV-gp55) was administered to commercially available outbred pigs via the subcutaneous or oral route and their susceptibility to 'in contact' challenge with classical swine fever determined. Animals vaccinated subcutaneously with a single dose of recombinant vaccine and challenged by 'in contact' exposure were protected from disease, whereas pigs given an equivalent single oral dose did not survive challenge. However, pigs given two oral doses of rPAdV-gp55, 22 days apart, were completely protected from disease. In addition, two doses of rPAdV-gp55 given subcutaneously was shown to boost CSFV neutralising antibody compared with a single dose, but neither a single dose nor two doses given orally induced detectable neutralising antibody responses.
Australian Animal Health Laboratory, CSIRO Livestock Industries, Private Mail Bag 24, Geelong, Vic. 3220, Australia.
Jef M
JM
Hammond
Elisa S
ES
Jansen
Christopher J
CJ
Morrissy
Adrian L M
AL
Hodgson
Michael A
MA
Johnson
D025662:Adenoviruses, Porcine / Q000235:genetics*; D000284:Administration, Oral; D000818:Animals; D006691:Classical Swine Fever / Q000517:prevention & control*; D006692:Classical Swine Fever Virus / Q000276:immunology*; D007115:Immunization Schedule; D007279:Injections, Subcutaneous; D013552:Swine; D014611:Vaccination / Q000662:veterinary; D014614:Vaccines, Synthetic / Q000008:administration & dosage; D014759:Viral Envelope Proteins / Q000235:genetics* / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage*
D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C087086:glycoprotein E2, classical swine fever virus